Bone biology, signaling pathways, and therapeutic targets for osteoporosis

Nicole M. Iñiguez-Ariza, Bart Clarke

Research output: Contribution to journalReview article

32 Scopus citations

Abstract

Major advances have occurred recently in the treatment of osteoporosis in recent years. Most patients are currently treated with bisphosphonates, denosumab, raloxifene, or teriparatide, and in some countries, strontium ranelate. Strontium ranelate and calcitonin have recently had their use restricted due to cardiovascular concerns and malignancy, respectively. The available agents have generally provided excellent options that effectively reduce fracture risk. New targets are being sought based on appreciation of the bone biology and signaling pathways involved in bone formation and resorption. These agents will directly target these signaling pathways, and further expand the options available for treatment of osteoporosis.

Original languageEnglish (US)
Pages (from-to)245-255
Number of pages11
JournalMaturitas
Volume82
Issue number2
DOIs
StatePublished - Oct 1 2015

Keywords

  • Anti-Dickkopf antibody
  • Anti-sclerostin antibody
  • Cathepsin K inhibitors
  • Osteoporosis
  • PTH
  • PTHrP

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Bone biology, signaling pathways, and therapeutic targets for osteoporosis'. Together they form a unique fingerprint.

  • Cite this